Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.

Beilhartz GL, Wendeler M, Baichoo N, Rausch J, Le Grice S, Götte M.

J Mol Biol. 2009 May 8;388(3):462-74. doi: 10.1016/j.jmb.2009.03.025. Epub 2009 Mar 13.

2.

Nucleic acid polymerases use a general acid for nucleotidyl transfer.

Castro C, Smidansky ED, Arnold JJ, Maksimchuk KR, Moustafa I, Uchida A, Götte M, Konigsberg W, Cameron CE.

Nat Struct Mol Biol. 2009 Feb;16(2):212-8. doi: 10.1038/nsmb.1540. Epub 2009 Jan 18.

3.
4.

Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates.

Liu S, Abbondanzieri EA, Rausch JW, Le Grice SF, Zhuang X.

Science. 2008 Nov 14;322(5904):1092-7. doi: 10.1126/science.1163108.

5.

Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.

Samuele A, Kataropoulou A, Viola M, Zanoli S, La Regina G, Piscitelli F, Silvestri R, Maga G.

Antiviral Res. 2009 Jan;81(1):47-55. doi: 10.1016/j.antiviral.2008.09.008. Epub 2008 Nov 5.

PMID:
18984007
6.

Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.

Tchesnokov EP, Obikhod A, Schinazi RF, Götte M.

J Biol Chem. 2008 Dec 5;283(49):34218-28. doi: 10.1074/jbc.M806797200. Epub 2008 Oct 20.

7.

Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".

Ehteshami M, Scarth BJ, Tchesnokov EP, Dash C, Le Grice SF, Hallenberger S, Jochmans D, Götte M.

J Biol Chem. 2008 Oct 31;283(44):29904-11. doi: 10.1074/jbc.M804882200. Epub 2008 Aug 25.

8.

Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.

Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, Wynhoven B, Harrigan PR, Götte M.

J Biol Chem. 2008 Aug 8;283(32):22222-32. doi: 10.1074/jbc.M803521200. Epub 2008 Jun 10.

9.

Dynamic binding orientations direct activity of HIV reverse transcriptase.

Abbondanzieri EA, Bokinsky G, Rausch JW, Zhang JX, Le Grice SF, Zhuang X.

Nature. 2008 May 8;453(7192):184-9. doi: 10.1038/nature06941.

10.

Structural probing of the HIV-1 polypurine tract RNA:DNA hybrid using classic nucleic acid ligands.

Turner KB, Brinson RG, Yi-Brunozzi HY, Rausch JW, Miller JT, Le Grice SF, Marino JP, Fabris D.

Nucleic Acids Res. 2008 May;36(8):2799-810. doi: 10.1093/nar/gkn129. Epub 2008 Apr 9.

11.

High-resolution NMR analysis of the conformations of native and base analog substituted retroviral and LTR-retrotransposon PPT primers.

Yi-Brunozzi HY, Brinson RG, Brabazon DM, Lener D, Le Grice SF, Marino JP.

Chem Biol. 2008 Mar;15(3):254-62. doi: 10.1016/j.chembiol.2008.01.012.

12.

RNase H activity: structure, specificity, and function in reverse transcription.

Schultz SJ, Champoux JJ.

Virus Res. 2008 Jun;134(1-2):86-103. doi: 10.1016/j.virusres.2007.12.007. Epub 2008 Feb 7. Review.

13.

Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription.

Nowotny M, Gaidamakov SA, Ghirlando R, Cerritelli SM, Crouch RJ, Yang W.

Mol Cell. 2007 Oct 26;28(2):264-76. Erratum in: Mol Cell. 2007 Nov 9;28(3):513.

14.

Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.

Mathiesen S, Dam E, Roge B, Joergensen LB, Laursen AL, Gerstoft J, Clavel F.

Antivir Ther. 2007;12(3):335-43.

PMID:
17591023
15.
16.

Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.

Marchand B, White KL, Ly JK, Margot NA, Wang R, McDermott M, Miller MD, Götte M.

Antimicrob Agents Chemother. 2007 Aug;51(8):2911-9. Epub 2007 May 21.

17.

Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.

Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK.

J Virol. 2007 Jul;81(13):6837-45. Epub 2007 Apr 11.

18.
19.

Two proton transfers in the transition state for nucleotidyl transfer catalyzed by RNA- and DNA-dependent RNA and DNA polymerases.

Castro C, Smidansky E, Maksimchuk KR, Arnold JJ, Korneeva VS, Götte M, Konigsberg W, Cameron CE.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4267-72. Epub 2007 Mar 5.

20.

HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site.

Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, McCoy-Simandle K, Ilina T, Clark AD Jr, Knight JL, Julias JG, Clark PK, Krogh-Jespersen K, Levy RM, Hughes SH, Parniak MA, Arnold E.

ACS Chem Biol. 2006 Dec 20;1(11):702-12.

Supplemental Content

Support Center